ArticleDiscover nano2026
Evaluation of the antivirulence and anticancer potential of green-synthesized silver/zinc oxide nanocomposites against methicillin-resistant Staphylococcus aureus and melanoma cells.
Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative In Vitro Response of HaCaT and A375 Melanoma Cells to Zinc Oxide Nanoparticles Synthesized Using Puerarin.Journal of xenobiotics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The escalating incidence of methicillin-resistant Staphylococcus aureus (MRSA) necessitates novel therapeutic strategies targeting antibiotic resistance and biofilm formation. Silver/zinc oxide nanocomposites (Ag/ZnO NCs) were green-synthesized using Pistacia atlantica leaf extract. Comprehensive characterization confirmed spherical nanocomposites with an average size of 18.1 nm and uniform distribution. The NCs exhibited strong antimicrobial activity with MICs of 0.25 and 0.125 mg/mL against clinical MRSA and S. aureus ATCC 6538, reducing biofilm formation by ~ 98%. Treatment at 1/2× MIC significantly downregulated biofilm-associated genes (icaA, icaD, clfA, clfB, fnbA) and the mecA resistance gene. Ag/ZnO NCs showed dose-dependent anticancer effects (IC₅₀ = 22.36 µg/mL) against melanoma A375 cells with lower cytotoxicity toward normal fibroblasts (IC₅₀ = 48.79 µg/mL) and notable antioxidant activity. These findings establish rationale for in vivo validation of green-synthesized Ag/ZnO NCs as multifunctional antimicrobial and anticancer agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.